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Edited by Robert BaroukiAbstract The aryl hydrocarbon (dioxin) receptor (AhR) has
been studied for several decades largely because of its critical
role in xenobiotic-induced toxicity and carcinogenesis. Albeit
this is a major issue in basic and clinical research, an increasing
number of investigators are turning their eﬀorts to try to under-
stand the physiology of the AhR under normal cellular condi-
tions. This is an exciting area that covers cell proliferation and
diﬀerentiation, endogenous mechanisms of activation, gene regu-
lation, tumor development and cell motility and migration,
among others. In this review, we will attempt to summarize the
studies supporting the implication of the AhR in those endoge-
nous cellular processes.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The Aryl hydrocarbon (dioxin) receptor (AhR) is a ligand-
activated transcription factor known to mediate most of the
toxic and carcinogenic eﬀects of a wide variety of environmen-
tal contaminants such as dioxin (TCDD; 2,3,7,8-tetrachlo-
rodibenzo-[p]-dioxin). This receptor belongs to the basic-
helix-loop-helix (bHLH)/PAS (Period [Per]-Aryl hydrocarbon
receptor nuclear translocator [Arnt]-Single minded [Sim]) fam-
ily of heterodimeric transcriptional regulators. bHLH/PAS
proteins are involved in the control of diverse physiological
processes such as circadian rhythms, organ development, neu-
rogenesis, metabolism and in the stress response to hypoxia
(reviewed in [1–3]). The large degree of conservation of this
receptor among species [4], its constitutive pattern of expres-
sion during development and in adult tissues [5] and the phe-Abbreviations: AhR, aryl hydrocarbon (dioxin) receptor; ARNT, aryl
hydrocarbon nuclear translocator; JNK, c-Jun N-terminal kinase;
TGFb, transforming growth factor b
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[6–8], have provided strong support for the involvement of
the AhR in cell physiology independently of xenobiotic metab-
olism. AhR activation is followed by changes in its compart-
mentalization within the cell. Whereas a large fraction of the
unliganded AhR resides in the cytosolic compartment bound
to a molecular chaperone complex (Hsp90/XAP2/p23), upon
ligand binding, the receptor translocates to the nucleus and
heterodimerizes with aryl hydrocarbon nuclear translocator
(ARNT). This heterodimer now binds to a partially character-
ized set of co-activators and/or co-repressors and the resulting
complex interacts with consensus regulatory sequences (xeno-
biotic response elements, XREs) located upstream in the
promoter of target genes (e.g. cytochromes P450 such as
CYP1A1) [3]. Once transcriptional regulation has occurred,
the AhR is exported to the cytosol and degraded by the protea-
some [9–11] (Fig. 1).
Although the molecular events leading to AhR activation in
presence of xenobiotics are generally well understood, AhR
signaling pathways in absence of exogenous ligands remain
largely unknown. Nevertheless, increasing experimental evi-
dence suggests physiological roles for the AhR in cell prolif-
eration and diﬀerentiation, in liver and immune system
homeostasis and in tumor development. Molecular mecha-
nisms for AhR activation in absence of xenobiotics remain elu-
sive in part because no deﬁnitive endogenous ligands have
been identiﬁed. Yet, novel means of receptor activation could
link the AhR to endogenous functions. Thus, this receptor can
be activated by natural compounds such as indirubin and indi-
go [12], an AhR repressor regulates AhR activity by binding
and sequestering ARNT [13], proteasome inhibition transcrip-
tionally activates the AhR in mouse embryo primary ﬁbro-
blasts in the absence of xenobiotics [11,14] and transient
over-expression of AhR and ARNT in CV-1 cells promotes
transcriptional activation of CYP1A1 in absence of exogenous
ligand [15]. Recently, several studies have shown that shear
stress activates the AhR and induces target gene expression
through a mechanism involving the release of an endogenous
ligand [16,17]. Moreover, the characterization of AhR hetero-
logues in invertebrates has provided evidence for the involve-
ment of such proteins in development, regardless the fact
that they are unable to bind xenobiotics [18,19]. Thus, the
xenobiotic-detoxifying function of the AhR could be a late-ac-
quired property that might have masked other ‘‘ancient’’ phys-
iological functions.blished by Elsevier B.V. All rights reserved.
Fig. 1. Transcriptional regulation of target genes by the AhR. Ligand binding to the AhR in the cytosol induces the release of a molecular chaperone
complex containing at least Hsp90, XAP2 and p23. This makes nuclear localization signals accessible for importing binding and nuclear
translocation. Once in the nucleus, ARNT is bound to the receptor and a transcriptionally active heterodimer is formed that can bind to consensus
regulatory sequences (XREs) located upstream in the promoter of target genes. After transcriptional regulation has occurred, the AhR dissociates
from ARNT and from the DNA and translocates again to the cytosol through exporting binding. In the cytosol, the AhR is degraded by the
proteasome.
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promote or inhibit cell proliferation, provide clues about phys-
iological processes that seem to require AhR activity and sug-
gest a role for this receptor in cell migration and human
cancer. Some of these issues have been the focus of excellent
reviews discussing diversity and evolution of the AhR [4], cell
cycle regulation and tumorigenesis [20,21], AhR cross-talk to
developmental signaling pathways [19] and dioxin-mediated
toxicity as compared to AhR-mediated physiological functions
[22].2. Endogenous role of the AhR in cell proliferation
Although most of the studies about AhR activation have
been done in presence of exogenous ligands, an increasing
body of evidence strongly suggests that this receptor can mod-
ulate cell proliferation in absence of xenobiotics, a conclusion
that supports its role in normal cell physiology.
2.1. Activation in the absence of xenobiotics
Early reports in cultured HeLa cells showed that a signiﬁ-
cant fraction of the AhR protein could be detected in the cell
nucleus in absence of exogenous ligand forming an active tran-
scriptional complex with ARNT [23]. Xenobiotic-independent
AhR activation was also observed in AhR-deﬁcient kidney
CV-1 cells, in which transient transfection of AhR and ARNT
induced nuclear translocation and reporter gene expression in
absence of exogenous ligand [15]. Experiments using the nucle-
ar export inhibitor leptomycin B have shown that the AhR
shuttles between cytosol and nucleus under normal cellular
conditions [24], while in the immune system, activation of B
lymphocytes with CD40 induced the AhR and increased
CYP1A1 in absence of exogenous ligands [25]. Therefore, these
and other reports have demonstrated AhR activation in cul-tured cells through mechanisms not requiring the presence of
xenobiotics. Nevertheless, they leave the question open of
whether, in vivo, changes in AhR levels would aﬀect cell and
tissue function.
2.2. Physiological clues about the endogenous roles of the AhR
Homologous recombination in embryonic stem (ES) cells
represents a major tool to decipher gene function in vivo.
The production of mouse lines lacking AhR expression by gene
targeting (gene knock-out) [6–8] has provided ﬁrst-hand infor-
mation about physiological processes requiring AhR activity.
These animal models not only demonstrated that this receptor
is essential for dioxin-induced toxicity [26] and carcinogenesis
[27], as presumable expected, but they also revealed the exis-
tence of an AhR-deﬁcient phenotype. In addition to cardiac
hypertrophy [28] and immune system and skin alterations
[8,29], the AhR has a physiological role in ovary development
that aﬀects reproduction. AhR-null females showed diﬃculties
in maintaining pregnancy and their pups had poor numbers of
survival during lactation and weaning [30]. Further studies re-
vealed that this reproductive defect could be associated to
alterations in the formation and number of primordial follicles
in the mouse ovary [31].
A well conserved alteration in AhR-null mouse models that
signiﬁcantly contributed to demonstrate the endogenous role
of this receptor is the hepatic phenotype. The livers of AhR-
null mice are smaller in size and show portal ﬁbrosis and early
lipid accumulation [6,8]. Vascular defects are also present that
include increased numbers of arteries and arterioles [29] and
portosystemic shunting in adult animals [32]. Gene expression
arrays have been used to compare liver mRNA proﬁles be-
tween wild type and AhR-null mice. In agreement with its
endogenous role in hepatic homeostasis, absence of AhR re-
sulted in changes in the expression pattern of 392 genes [33].
One of these genes, which appears as a potential candidate
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factor b (TGFb). Livers of AhR-null mice have increased levels
of TGFb in the portal areas [34] that could contribute to the
development of ﬁbrosis and to a lower proliferation rate due
to the proﬁbrogenic and anti-proliferative activities of this
cytokine. Additional studies have shown that the increased lev-
els of TGFb could, in fact, be related to retinoic acid accumu-
lation and reduced retinoic acid metabolism, resulting from
downregulation of CYP2C39, a major cytochrome P450 able
to catalyze retinoic acid 4-hydroxylase reactions in the liver
[35,36]. Therefore, many diﬀerent studies, in several organs
and target tissues, strongly support that the AhR is relevant
to preserve normal cell physiology and give a clue about its rel-
evance in diseased states.2.3. The AhR as a positive regulator of cell proliferation
One of the most intriguing and exciting aspects of AhR biol-
ogy is the ability of this receptor to promote or to inhibit cell
proliferation depending on the cell’s phenotype. Reports have
been published clearly showing that the characteristics of a
particular cell profoundly aﬀect whether it will grow or not
upon AhR activation or over-expression. This has important
implications if the AhR is to be considered a molecular marker
in such human diseases as cancer.
The AhR cooperates with signaling molecules involved in
survival pathways that sustain cell proliferation. One such
molecule is NF-jB with which the AhR physically interacts
through the p65/RelA subunit in human breast cancer MCF-
7 cells [37]. The interaction between AhR and p65/RelA re-
sulted in transactivation of the c-myc proto-oncogene, thus
oﬀering a mechanism whereby this receptor could contribute
to increased proliferation and carcinogenesis in the breast. Cel-
lular AhR protein content is also relevant to induce prolifera-
tion since its over-expression in human lung carcinoma A549
cells increased E2F/DP2 activation, proliferating cellular nu-
clear antigen (PCNA) levels and proliferation rates [38]. Inter-
estingly, mouse models over-expressing a constitutively active
form of the AhR, which resemble a maintained TCDD-activa-
tion status, also demonstrated the role of this receptor as pro-
liferation promoter. Mice expressing a constitutively active
AhR showed an increased frequency of N-nitrosodiethyl-
amine-induced hepatocarcinomas [39] and spontaneous tu-
mors in the glandular stomach [40]. Thus, in deﬁned cellular
phenotypes, AhR over-expression and/or activation stimulate
proliferation and even carcinogenesis. From these reports, it
can be proposed that this receptor has oncogenic activity.2.4. The AhR as a negative regulator of cell proliferation
There are also diﬀerent reports demonstrating that the AhR
has anti-proliferative activity. An initial study showed that,
upon activation with exogenous ligand, the AhR transcription-
ally activated the tumor suppressor p27Kip1 in non-proliferat-
ing 5L hepatoma cells, and that p27Kip1-induction by dioxin
in fetal thymus occurred along with the inhibition of cell pro-
liferation [41]. A set of studies has later proposed that the anti-
proliferative activity of the AhR takes place, at least in part,
through its physical interaction with the retinoblastoma
(pRb) tumor suppressor protein, a process resulting in pRb-
mediated inhibition of E2F-dependent transcription and cell
cycle arrest. The AhR synergizes and interacts with pRb in
presence of exogenous ligands in basal MCF-7 human breastcancer cells and in transiently transfected SAOS-2 human oste-
osarcoma cells [42]. In addition, the cell cycle blockade at G1
induced by dioxin in MCF-7 and mouse hepatoma Hepa-1
cells was dependent on the interaction between activated
AhR and the p300 co-activator, a process inducing displace-
ment of p300 from E2F-dependent promoters and prolifera-
tion arrest [43].
Constitutive AhR expression has been a useful tool to ana-
lyze the inhibitory role of this receptor in cell proliferation.
Constitutively active AhR arrested cell cycle at G1 and induced
apoptosis in Jurkat T cells, in part by regulating the expression
of proliferation- and apoptosis-related genes through XRE-
dependent mechanisms [44]. In the immune system, transgenic
mice containing a constitutively active AhR targeted to T cells
by the CD2 promoter had lower thymocyte numbers and
altered diﬀerentiation [45]. Experiments using mouse thymus
in organ culture revealed that AhR activation by TCDD
inhibited proliferation in immature CD4CD8 and
CD4CD8+HAS+ thymocytes whereas it accelerated the mat-
uration of thymocytes [46,47]. Further, dioxin altered cell cycle
progression, specially in CD4CD8CD3 lymphocytes, by
increasing the percentage of cells at G1 and by decreasing
the population at G2/M [48]. These studies again emphasize
that the eﬀect of AhR in cell proliferation is highly dependent
on cell phenotype. Interestingly, two recent reports have
shown that sustained AhR activation inhibits the regenerative
growth of the caudal ﬁns in zebraﬁsh [49] and liver regenera-
tion after 2/3 partial hepatectomy in mice, probably by a mech-
anism involving cyclin-dependent kinase 2 (CDK-2) but not
p27Kip1 or p21Cip1 [50]. Together, these studies argue for a
tumor suppressor activity of the AhR in the control of cell pro-
liferation.
This dual eﬀect of the AhR on cell proliferation became also
evident from a report in which receptor levels were dowregu-
lated by transient transfection of speciﬁc small interfering
RNAs (siRNAs) [51]. In MCF-7 human breast cancer cells,
AhR siRNAs promoted the G1/S transition of the cell cycle
and cell proliferation, suggesting a growth inhibitory role of
the receptor. In contrast, in HepG2 human hepatoma cells,
AhR siRNAs blocked the G1/S transition of the cell cycle
and downregulated cyclin D1, cyclin E and CDK-2/4, thus
revealing a growth promoting activity of the receptor.
Therefore, it appears that cell phenotype is a critical param-
eter in determining whether the AhR will promote (oncogenic)
or inhibit (tumor suppressor) cell growth and proliferation.
Further studies are needed to clarify not only the speciﬁc sig-
naling pathways involved but also the intermediate proteins
interacting with the AhR.3. Novel cellular functions of the AhR
3.1. Developmental functions in invertebrates
The AhR has been identiﬁed in several invertebrates such as
the ﬂy Drosophila melanogaster and the worm Caenorhabditis
elegans. Spineless (ss) is a bHLH–PAS Drosophila protein
considered to be an AhR ortholog. It plays a central role in
deﬁning the distal regions of both antennae and leg. Loss-of-
function alleles of ss cause several developmental defects:
transformation of distal antenna into leg, deletion of distal
leg (tarsal) structures, and reduction in size of most bristles
[52]. The identity of the target genes and the gene network
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Like AhR, ss functions as a heterodimer with the Drosophila
ortholog of ARNT, Tango. Spineless-Tango heterodimers
are very similar to AhR-ARNT heterodimers in their DNA-
binding speciﬁcity and transcriptional activation ability. How-
ever, the interaction of ss with Tango does not seem to require
the presence of classical ‘‘mammalian AhR ligands’’ [54]. Re-
cent reports have suggested that ss is also important in neuro-
nal development, especially in the diversiﬁcation of the
dendritic morphology of some specialized sensory neurons
and as a major determinant in the Drosophila retinal mosaic
eye [58].
The importance of ss in ﬂy neuron functions is interesting in
the light of several recent publications on AhR orthologs in
another invertebrate, the nematode Caenorhabditis elegans.
The corresponding proteins, AHR-1 and AHA-1 (ortholog
of ARNT) also share biochemical properties with their mam-
malian cognates. However, like ss, AHR-1 does not appear
to be activated by dioxin or beta-naphthoﬂavone [59]. The
expression pattern of AHR-1 is particularly interesting since
it is expressed in GABAergic motor neurons (named RMEL
and RMER) and it regulates their fate speciﬁcation [60]. More-
over, in AHR-1-deﬁcient animals, the touch receptor neuron
AVM, as well as other neuronal subtypes, exhibit cell and ax-
onal migration defects. The authors suggest the involvement of
TGFb (UNC-129) in this process, a particularly relevant
observation since TGFb and AhR signalling pathways cross-
talk in numerous mammalian systems [59]. Finally, another
study has shown that loss-of-function mutations in AHR-1
or AHA-1 suppress neuropeptide receptor-1 (npr-1)-related
aggregation and regulates cell-type-speciﬁc expression of solu-
ble guanylate cyclase genes that have key roles in aggregation
behaviour and hyperoxia avoidance [61].
All these results show that AhR has important physiological
roles in invertebrates and that it regulates developmental pro-
cesses. Remarkably, a common feature in these models is the
implication of the AhR in neuronal diﬀerentiation and func-
tion. However, this particular aspect of AhR biology has not
been extensively studied in mammalian systems probably be-
cause of the prevalence of xenobiotic metabolism-oriented
studies. Further work is required since epidemiological obser-
vations have suggested that dioxin exposure was associated
with neurodevelopmental, cognitive and behavioral defects
[62].3.2. Functions related to cell adhesion and migration
The contribution of the AhR to adhesion processes involv-
ing cell–cell and cell–substratum interactions is only beginning
to emerge, and several laboratories are currently trying to
determine at which level the AhR interacts with those signaling
pathways. Since cell–cell and cell–substratum interactions have
a profound impact in cell migration, and cell migration is di-
rectly related to the metastatic potential of tumor cells, these
correlations make this issue worth of investigation.
Early work showed that when adherent normal human
keratinocytes are induced to go into suspension in the absence
of xenobiotics, the AhR became activated and CYP1A1 in-
duced, suggesting that physiological control of cell adhesion
in stratiﬁed squamous epithelia could, under certain condi-
tions, activate this receptor [63]. Further, suspension of adher-
ent mouse hepatoma Hepa-1c1 cells also induced nucleartranslocation and transcriptional activation of the AhR in
the absence of xenobiotics [64], again suggesting that this
receptor could be activated during changes in the adhesion sta-
tus of the cell.
Additional studies point to the hypothesis that preventing
cell–cell contacts activate the AhR. The suspension of
C3H10T1/2 ﬁbroblasts stimulated AhR activation and induced
reporter gene expression to levels similar to those obtained by
exogenous ligand [65]. However, an interesting diﬀerence be-
tween both mechanisms is that suspension-induced was more
transient than xenobiotic-induced activation. The use of phar-
macological inhibitors suggested that this transient eﬀect could
be due to diﬀerences in transcriptional activation rather than
in nuclear translocation and/or DNA binding eﬃciency of
the receptor. Further experiments performed at low cell den-
sity revealed that cell–cell contact had a prominent role over
the lack of cell–substratum interactions to induce AhR activa-
tion, suggesting that cell density can regulate intracellular AhR
distribution, with the trancriptionally inactive receptor located
in the cytosol at conﬂuence and the transcriptionally active
receptor present in the nucleus at sparse cell densities [65]. In
agreement with these observations, the AhR was mainly nucle-
ar in low density cultures of the keratinocyte cell line HaCaT,
both nuclear and cytoplasmatic at subconﬂuence and predom-
inantly cytosolic at conﬂuence [66]. By introducing mutations
in the nuclear localization signal of the AhR, it was possible
to suggest that this diﬀerential distribution was due to modu-
lation of the nuclear export activity of the cell [66].
The correlation between AhR activity and cell migration is
still diﬀuse at the present time. Work done analyzing the C.
elegans AHR-1 has shown that AHR-1-null animals have de-
fects in neuronal diﬀerentiation that are due, among other
causes, to aberrant axonal migration [59]. The regulator of
the epithelial–mesenchymal transition (EMT) Slug has been re-
cently reported to be induced by the AhR in the keratinocyte
cell line HaCaT [67]. From this study, it was found that tran-
scriptional activation of Slug was coincident with nuclear
translocation of the AhR. Further, in wound healing experi-
ments in culture, Slug and the AhR co-localized in the nucleus
of cells located at the margin of the wound. These results not
only conﬁrm AhR activation when cell–cell contacts are dis-
rupted, but also open the possibility that the AhR could inter-
act with speciﬁc cell adhesion molecules. The contribution of
the AhR to cell migration is also supported by studies in the
immune system. Recent reports have shown that, in thymic or-
gan cultures, AhR ligands cause a preferential emigration of
CD4CD8 double negative cells expressing the CD44v7
and CD44v10 variant isoforms [68]. In vivo, AhR over-activa-
tion induced CD4CD8 emigration to the periphery and
accumulation in the spleen; gene expression analysis of a sub-
set of these recent thymic emigrants revealed the upregulation
of at least 15 genes, among them the S100A9 gene [69].
We have recently shown that immortalized mouse mammary
ﬁbroblasts from AhR-null mice had decreased migration in
culture and that this phenotype was associated to an increase
in stress ﬁber formation and to a lower eﬃciency to induce
lamellipodia [70]. Signaling pathways that regulate cell migra-
tion were also inhibited in AhR-null cells, and thus, we found
lower activation of focal adhesion kinase (FAK), protein ki-
nase B/AKT (PKB/AKT), mitogen activated kinase ERK1
and Rac-1. Moreover, AhR-null immortalized ﬁbroblasts, as
opposed to wild type cells, had a much lower eﬃciency to
RTKs
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Fig. 2. The AhR interacts with signalling pathways controlling cell adhesion and migration. As a model, signalling regulating focal adhesion
dynamics and lamellipodia formation is represented. From tyrosine kinase receptors (RTKs) signals are transduced to plasma membrane associated
protein complexes containing, among others, focal adhesion kinase (FAK). Other molecules such as phosphoinositide 3-kinase (PI3K) and small
GTPases of the Rac and Rho family also associates to these protein structures. Whereas FAK is mainly involved in focal adhesion dynamics with the
substratum, Rac/Rho are involved in actin cytoskeleton reorganization and lamellipodia/philopodia formation. Molecules altering these pathways
are expected to change the adhesion/migration pattern of the cell. The AhR and JNK could act at diﬀerent levels in these pathways and some
possibilities (not excluding many others) are indicated by arrows and question marks.
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From these data, we suggested that their lower migration abil-
ity compromised the potential of AhR-null immortalized ﬁbro-
blasts to induce tumors in vivo and that, in this cell line, the
AhR could have oncogenic activity (Fig. 2).
The implication of the AhR in cell plasticity and mobility is
also supported by studies using xenobiotic ligands for this
receptor. Indeed, we have recently shown that TCDD-treated
mammary carcinoma MCF-7 cells display cell scattering, in-
creased cell surface, appearance of lamellipodia-like protru-
sions and subsequent higher cell adherence and motility.
Those morphological changes are associated with cytoskeleton
reorganization, mainly through vinculin and actin redistribu-
tion. These cellular eﬀects are accompanied by changes in the
expression of several genes; notably, a decrease in E-Cadherin
that could help explain the previously described cellular alter-
ations. Concomitantly, TCDD was shown to activate c-Jun N-
terminal kinases (JNKs), which were found to be required for
the dioxin eﬀects on cell morphology and mobility [71] (Fig. 2).
While those cellular eﬀects of the AhR seem not to be related
to adaptation to xenobiotic exposure, they may still be mech-
anistically connected to the induction of xenobiotic metaboliz-
ing enzymes. Indeed, CYP1A1 is the most potently induced
gene following AhR activation. It has been shown that
CYP1A1 activity is associated with the release of reactive oxy-
gen species (ROS), which may account for the oxidative stress
that is observed following exposure to AhR ligands [72–74].
ROS display a wide variety of cellular eﬀects, among which,
JNK activation and induction of cellular mobility have to be
considered. It is thus possible that some of the cellular eﬀectsof AhR activation may be related to the induction of CYP
genes and to a consequent increase in ROS.
A recent experimental approach helpful to deﬁne signaling
pathways that integrate the AhR in toxicology, proliferation,
migration and cell adhesion is based on microarray expression
proﬁling. Liver mRNA microarray analysis after TCDD treat-
ment identiﬁed changes in gene expression that could be clus-
tered to proliferation, apoptosis, oxidative metabolism and
diﬀerentiation, among others [75]. Treatment of Sprague–
Dawley rats with the toxin A277249 changed hepatic gene
expression in such a way that implicated the AhR in the toxic
process [76]. Moreover, comparison of the transcriptome of
CD4 cells from wild type and AhR-null mice discovered the
existence of 390 genes deregulated in the mutant cells, been a
large number of them immunotypic [77]. Finally, a meta-anal-
ysis of 1967 Aﬀymetrix microarrays hybridized with the tran-
scriptomes of more than 100 murine cell lines revealed cell
type- and diﬀerentiation-speciﬁc expression of AhR, ARNT
and HIF-1a in the T-cell lineage. This same study reported
53 potential cellular situations in which the AhR was regu-
lated, many conditions modifying intrinsic AhR functions
and numerous status in which the AhR was activated in the
absence of exogenous ligands [78].
Thus, it appears plausible to hypothesize that the AhR par-
ticipates in signaling pathways regulating cell–cell and cell–
substratum adhesion and, by extension, that this receptor
could have a role in cell migration. Alteration of this signaling
due to changes in AhR levels/activity could contribute to
abnormal cell migration, potentially aﬀecting the tumorigenic
potential of the target cell.
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absence of xenobiotics
A major question in human cancer is the identiﬁcation of
molecular markers helpful not only for the early diagnosis of
the disease but also to predict treatment eﬃcacy and speciﬁcity
in individual tumors and patients. Although this is a long-term
goal in AhR research, some recent reports suggest that this
receptor could be relevant in human cancer.
The AhR appears to have constitutive expression and activ-
ity in established cell lines from human adult T-cell leukemia
(ATL) and in some primary ATL cell cultures [79], which sug-
gest that this receptor has oncogenic activity in this tumor
type. We have recently shown that the human AhR promoter
has CpG islands prone to be methylated, and that whereas
human tumor cell lines expressing AhR have unmethylated
promoter, those cell lines not expressing this protein have a
heavily methylated promoter [80]. In particular, acute lympho-
blastic leukemia (ALL) REH and chronic myeloid leukemia
(CML) K562 cell lines did not express AhR and had higher
levels of AhR promoter methylation. Furthermore, the AhR
was methylated in 33% of 21 human primary ALL tumors,
which suggested that AhR silencing in this tumor type could
be reﬂecting a tumor suppressor activity for this receptor.
Interestingly, the frequency of AhR methylation in ALL was
similar to that found for tumor suppressors p53, p73, p15
and p16 [80]. Therefore, it can be observed that depending
on the phenotype of the human tumor, and as previously dis-
cussed, the AhR could correlate with increased or with de-
creased proliferation potential and, thus, behave as an
oncogen or as a tumor suppressor gene.
Because changes in AhR levels and activity could be relevant
to human cancer, some studies have addressed whether speciﬁc
AhR ligands can be useful as chemotherapeutic agents to mod-
ulate the activity of this receptor in human tumors (reviewed in
[81]). In pancreatic cancer tissue samples, AhR protein was ex-
pressed at high levels and localized mainly in the cytosolic
compartment of the cell. Interestingly, the proliferation and
anchorage-independent growth of these cells were inhibited
by several AhR agonists, suggesting that these or related com-
pounds could be relevant in the therapy of pancreatic cancer
[82].
Thus, although much more work has to be done, it appears
that the AhR has a role in human cancer by interacting with
signaling pathways in a cell type-speciﬁc manner. It is plausible
to suggest that this receptor could become a useful tool in the
detection and treatment of this disease.5. Concluding remarks
The AhR ﬁeld is beneﬁting from intense investigation cover-
ing both xenobiotic-related and unrelated issues. From either
perspective, new and exciting results are arising that propose
this cellular receptor as a relevant target in human disease.
The fact that this receptor remains active under physiological
conditions is an important argument to screen for cellular pro-
cesses where its activity may be required. Moreover, the AhR
does not seem to require any ligands in invertebrates where it
regulates important developmental processes. Its rather inter-
esting behavior with regard to the control of cell proliferation
makes this protein an attractive model and a potential target inhuman cancer. An additional aspect of AhR biology,
also quite appealing, is its contribution to the regulation of
cell adhesion and migration, two processes highly important
in development and cancer. It is clear from the point of view
of the endogenous role of the AhR that much more work is
needed in various species. However, the studies performed
so far are providing evidences about which cellular func-
tions may be relevant to locate this receptor within physiolog-
ical pathways controlling cell functioning in health and
disease.
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